67 related articles for article (PubMed ID: 25128202)
1. HIF-1-dependent heme synthesis promotes gemcitabine resistance in human non-small cell lung cancers via enhanced ABCB6 expression.
Xiang L; Wang Y; Lan J; Na F; Wu S; Gong Y; Du H; Shao B; Xie G
Cell Mol Life Sci; 2022 Jun; 79(6):343. PubMed ID: 35661930
[TBL] [Abstract][Full Text] [Related]
2. Levofloxacin increases the effect of serum deprivation on anoikis of rat nucleus pulposus cells via Bax/Bcl-2/caspase-3 pathway.
Yang SD; Bai ZL; Zhang F; Ma L; Yang DL; Ding WY
Toxicol Mech Methods; 2014 Dec; 24(9):688-96. PubMed ID: 25224805
[TBL] [Abstract][Full Text] [Related]
3. The histone deacetylase inhibitor, Vorinostat, represses hypoxia inducible factor 1 alpha expression through translational inhibition.
Hutt DM; Roth DM; Vignaud H; Cullin C; Bouchecareilh M
PLoS One; 2014; 9(8):e106224. PubMed ID: 25166596
[TBL] [Abstract][Full Text] [Related]
4. Repurposing FDA approved drugs as radiosensitizers for treating hypoxic prostate cancer.
Bibby BAS; Thiruthaneeswaran N; Yang L; Pereira RR; More E; McArt DG; O'Reilly P; Bristow RG; Williams KJ; Choudhury A; West CML
BMC Urol; 2021 Jul; 21(1):96. PubMed ID: 34210300
[TBL] [Abstract][Full Text] [Related]
5. Gemcitabine Co-Encapsulated with Curcumin in Folate Decorated PLGA Nanoparticles; a Novel Approach to Treat Breast Adenocarcinoma.
Mukhopadhyay R; Sen R; Paul B; Kazi J; Ganguly S; Debnath MC
Pharm Res; 2020 Feb; 37(3):56. PubMed ID: 32072346
[TBL] [Abstract][Full Text] [Related]
6. Fixed-dose-rate administration of gemcitabine in cancer-bearing cats: A pilot study.
Garnett CL; Guerrero TA; Rodriguez CO
Can Vet J; 2016 Nov; 57(11):1149-1155. PubMed ID: 27807377
[TBL] [Abstract][Full Text] [Related]
7. Modeling Combined Chemotherapy and Particle Therapy for Locally Advanced Pancreatic Cancer.
Durante M; Tommasino F; Yamada S
Front Oncol; 2015; 5():145. PubMed ID: 26217585
[TBL] [Abstract][Full Text] [Related]
8. The hypoxic tumor microenvironment and drug resistance against EGFR inhibitors: preclinical study in cetuximab-sensitive head and neck squamous cell carcinoma cell lines.
Boeckx C; Van den Bossche J; De Pauw I; Peeters M; Lardon F; Baay M; Wouters A
BMC Res Notes; 2015 Jun; 8():203. PubMed ID: 26032726
[TBL] [Abstract][Full Text] [Related]
9. Hypoxia regulates ABCG2 activity through the activivation of ERK1/2/HIF-1α and contributes to chemoresistance in pancreatic cancer cells.
He X; Wang J; Wei W; Shi M; Xin B; Zhang T; Shen X
Cancer Biol Ther; 2016; 17(2):188-98. PubMed ID: 26785721
[TBL] [Abstract][Full Text] [Related]
10. The radiosensitising effect of gemcitabine and its main metabolite dFdU under low oxygen conditions is in vitro not dependent on functional HIF-1 protein.
Wouters A; Pauwels B; Burrows N; Baay M; Deschoolmeester V; Vu TN; Laukens K; Meijnders P; Van Gestel D; Williams KJ; Van den Weyngaert D; Vermorken JB; Pauwels P; Peeters M; Lardon F
BMC Cancer; 2014 Aug; 14():594. PubMed ID: 25128202
[TBL] [Abstract][Full Text] [Related]
11. The radiosensitising effect of difluorodeoxyuridine, a metabolite of gemcitabine, in vitro.
Pauwels B; Korst AE; Lambrechts HA; Pattyn GG; de Pooter CM; Lardon F; Vermorken JB
Cancer Chemother Pharmacol; 2006 Aug; 58(2):219-28. PubMed ID: 16331496
[TBL] [Abstract][Full Text] [Related]
12. The relation between deoxycytidine kinase activity and the radiosensitising effect of gemcitabine in eight different human tumour cell lines.
Pauwels B; Korst AE; Pattyn GG; Lambrechts HA; Kamphuis JA; De Pooter CM; Peters GJ; Lardon F; Vermorken JB
BMC Cancer; 2006 May; 6():142. PubMed ID: 16734894
[TBL] [Abstract][Full Text] [Related]
13. An undesired effect of chemotherapy: gemcitabine promotes pancreatic cancer cell invasiveness through reactive oxygen species-dependent, nuclear factor κB- and hypoxia-inducible factor 1α-mediated up-regulation of CXCR4.
Arora S; Bhardwaj A; Singh S; Srivastava SK; McClellan S; Nirodi CS; Piazza GA; Grizzle WE; Owen LB; Singh AP
J Biol Chem; 2013 Jul; 288(29):21197-21207. PubMed ID: 23740244
[TBL] [Abstract][Full Text] [Related]
14. Hypoxia-inducible factors are required for chemotherapy resistance of breast cancer stem cells.
Samanta D; Gilkes DM; Chaturvedi P; Xiang L; Semenza GL
Proc Natl Acad Sci U S A; 2014 Dec; 111(50):E5429-38. PubMed ID: 25453096
[TBL] [Abstract][Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
